Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials by Silverberg, J.I. et al.
This is a repository copy of Dupilumab significantly modulates pain and discomfort in 
patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials.




Silverberg, J.I., Simpson, E.L., Guttman-Yassky, E. et al. (15 more authors) (2021) 
Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a






This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Dupilumab Significantly Modulates Pain and
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Background: Pain is a frequent symptom of atopic dermatitis (AD).
Objectives: The aims of the study were to evaluate the effects of dupilumab on pain/discomfort in AD and to determine
whether pain correlates with other outcomes.
Methods: This was a post hoc analysis of 5 randomized, placebo-controlled clinical trials in which adults with chronic
AD received placebo or dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids. Pro-
portions of patients with no pain/discomfort on this dimension of the 5-dimension EuroQoL (EQ-5D) at week 16 (all trials)
and week 52 (CHRONOS) were compared between placebo and dupilumab. Correlations were evaluated between pain/
discomfort and signs and symptoms of AD.
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Results: Among 2632 evaluated patients, 72.9% to 83.1% reported at least moderate pain/discomfort at baseline. Higher
proportions treated with dupilumab reported no pain/discomfort at week 16 relative to placebo; risk differences ranged from
22.3% (95% confidence interval = 11.5%–33.1%) to 42.2% (95% confidence interval = 26.6%–57.8%, all P ≤ 0.0001), with sim-
ilar effects observed at week 52. Correlations at baseline of pain/discomfort with signs and symptoms of AD were low to
moderate.
Conclusions: Pain/discomfort, present in a substantial proportion of patients with moderate-to-severe AD, was signifi-
cantly reduced by dupilumab treatment. Given the low-to-moderate correlations with other AD symptoms at baseline, pain
likely represents a distinct AD symptom.
Trial Registration: ClinicalTrials.gov identifiers NCT01859988,
NCT02277743, NCT02277769, NCT02260986, andNCT02755649.
T he pathophysiology of atopic dermatitis (AD) is characterizedby skin barrier disruption and inflammation mediated by a
type 2 immune response.1–4 Itch (pruritus) is considered the cardi-
nal symptom of AD5,6 and has a well-recognized impact, affecting
sleep, mental health, and health-related quality of life (HRQoL).7,8
By contrast, pain has not been well characterized in patients with
AD, despite being rated as very important by more than 80% of re-
spondents in an international survey of more than 1000 patients
with AD.6 The lack of such information has been identified as an
important research gap,9 and control of pain, as well as other related
sensations that may cause discomfort in patients with AD, such as
burning and increased sensitivity to touch, remains an unmet need
among patients with moderate-to-severe AD.
Emerging data from several studies suggest that pain in patients
with AD is an important and potentially independent symptom that
contributes to the disease burden.10–12 Pain is among the top 3 most
frequent symptoms associated with AD, which also include itching
and sleep difficulties.5 Pain is one of the most frequent words, iden-
tified through text mining analysis, that patients use to describe the
impact of ADon their life,13 and pain is a close second to itch among
the AD symptoms that matter to patients when determining the ef-
fectiveness of treatment response.6
The presence of pain in substantial proportions of patients with
AD has consistently been reported,5,10,11,14,15 and it has been esti-
mated that the prevalence of any pain from AD is 61%, with more
than half of these patients (54.5%) reporting pain at least once per
week.15 In a clinic-based study that was specific to pain, somatic
pain within the past week was reported by 42.7% of patients with
AD regardless of AD severity, of whom 29.2% reported their pain
as severe/very severe.10 Although the reported prevalence of pain
in this population was higher in patients with excoriations com-
pared with those without (72.6% vs 57.6%, P = 0.02), it should be
noted that more than half of the patients without excoriations still
reported pain. Another study in patients with AD and chronic itch
reported hyperknesis (greater perception of provoked itch) and in-
creased sensitivity to mechanically induced pain at both lesional
and nonlesional skin sites,16 suggesting that the pain may be inde-
pendent of excoriations, or it might reflect centralization and receptive
field recruitment.17 A study from an international dermatology prac-
tice-based survey of patients with AD reported that 78% of patients
had concomitant pain and itch, with approximately 15% of the partic-
ipants reporting pain in both active lesions and nonlesional skin.11
Such emerging data on pain/discomfort in patients with AD sug-
gest the need for greater understanding of these symptoms in AD,
including their contribution to the disease burden and the effects
of therapy on these outcomes. Dupilumab, a fully human monoclo-
nal antibody that targets interleukin-4 receptor alpha (IL-4Rα) and
inhibits both IL-4 and IL-13 signaling, has demonstrated significant
reductions in itch as well as improvements in clinical and
patient-reported outcomes in patients with moderate-to-severe
AD in multiple clinical trials.18–23 The objective of this study was
to better understand pain in AD and its relationship to other AD
outcomes using the pain/discomfort item of the 3-level version of
the 5-dimension EuroQoL (EQ-5D-3L) instrument measured in
clinical trials of dupilumab and to determine the effect of dupilumab
therapy on this outcome.
METHODS
Study Design and Populations
Data included in this report are post hoc analyses from published
randomized, double-blind, placebo-controlled trials that evaluated
the efficacy and safety of dupilumab for the treatment of adults with
moderate-to-severe AD. These studies included a phase 2b clinical
trial (Study 1021, NCT01859988)18 and 4 phase 3 trials: LIBERTY-AD
SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769),19
LIBERTY-AD CHRONOS (NCT02260986),24 and LIBERTY-AD
CAFÉ (NCT02755649).22Although the study designs for these trials
have previously been reported, brief summaries of relevant methods
are provided hereinafter. The current analysis presents data for the
placebo and dupilumab 300 mg weekly (qw) and every 2-week
(q2w) treatment groups from each of the trials, although the phase
2b study also included other dose regimens.
For inclusion in all trials, patients were required to be adults
(18 years or older) with chronic AD for 3 years or more before
screening and to meet the following criteria at baseline: an
Investigator's Global Assessment score of 3 or higher (on a 0- to
4-point Investigator's Global Assessment scale), corresponding to
at least moderate disease; body surface area of AD involvement of
10% or greater; an Eczema Area and Severity Index (EASI) score
of 16 or higher (phase 2b, SOLO 1&2, and CHRONOS) or 20 or
higher (CAFÉ); and a Pruritus Numerical Rating Scale (NRS) aver-
age score for maximum itch intensity of 3 or more (SOLO 1&2,
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CHRONOS). In the phase 2b study, patients with AD not adequately
controlled by topical treatments, or for whom topical treatment was
inadvisable, were randomized to 16 weeks of treatment18; SOLO 1
and SOLO 2 were identically designed 16-week monotherapy trials
that consisted of populations similar to the phase 2b study.19
CHRONOS was conducted to evaluate the long-term (52 weeks) ef-
ficacy and safety of dupilumab when used with concomitant topical
corticosteroids (TCSs) with or without topical calcineurin inhibi-
tors, as well as a documented recent history of inadequate response
to medium- to high-potency TCS (± topical calcineurin inhibitor as ap-
propriate).24 These patients were randomized to 52 weeks of treatment
with dupilumab + TCS, or placebo + TCS. The CAFÉ trial evaluated the
efficacy and safety of dupilumab with concomitant TCS in adult pa-
tients whose disease was not adequately controlled with, or who were
intolerant to, oral cyclosporine A, or for whom cyclosporine A was
not medically advisable.22 Patients were randomized to 16 weeks of
treatment with dupilumab + TCS or placebo + TCS.
Outcomes
The EQ-5D is the most commonly used standardized instrument
for assessing generic HRQoL across a wide range of chronic condi-
tions.25,26 The EQ-5D-3L, which was included in all the dupilumab
trials, consists of 5 dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression), of which the pain/discomfort
dimension is the focus of the current analysis. The 3 levels of re-
sponse for this dimension are “no pain or discomfort,” “moderate
pain or discomfort,” and “extreme pain or discomfort.” The evalu-
ated outcome was percentage of patients who reported “no pain
or discomfort” at the evaluated time points. The relationship be-
tween pain/discomfort and outcomes was also investigated using
data that were pooled from the SOLO 1&2 + CHRONOS trials. This
includedAD signs (EASI, Scoring Atopic Dermatitis [SCORAD] to-
tal score, and individual signs), AD symptoms (peak pruritus NRS,
Patient-Oriented Eczema Measure [POEM]),27HRQoL (Dermatol-
ogy Life Quality Index [DLQI]),28 and symptoms of anxiety and de-
pression assessed using the Hospital Anxiety and Depression Scale
(HADS),29 which includes subscales for anxiety and depression.
Statistical Analyses
Analyses were conducted using the full analysis set. Risk differences
for proportions of patients who reported “no pain or discomfort” re-
flect dupilumab minus placebo, with 95% confidence interval (95%
CI) calculated using normal approximation. Comparisons between
the dupilumab and placebo groups were conducted using the
Cochran–Mantel–Haenszel test; values after first rescue treatment
used were set to missing (censoring), and patients with missing as-
sessment were considered nonresponders.
The relationships between pain/discomfort and other outcomes
were evaluated using Spearman rank correlation coefficients, which
were estimated post hoc. These correlation analyses were conducted
on baseline scores. In addition, for those patients who reported at
least “moderate pain/discomfort” on the EQ-5D-3L at baseline,
correlations were assessed for changes from baseline in outcomes
at week 16 for the combined patient population from SOLO
1&2 + CHRONOS trials. Spearman coefficients (r) 0.10 to 0.29,
0.3 to 0.49, and greater than 0.50 indicate low, moderate, and strong
associations, respectively.30Data were pooled across treatment arms
and trials for the correlation analyses because the hypotheses being
tested revolved around the relationship between improvements in
pain and other outcomes regardless of why the improvement oc-
curred (drug or placebo with or without TCS).
To further explore the relationship between pain/discomfort and
scratching, that is, if scratching was a potential source of patient-
reported pain/discomfort, baseline treatment groups were pooled
in each study and evaluated for the proportions of patients who
had each level of reported response for EQ-5D-3L pain/discomfort
(no, moderate, and extreme) stratified by the level of severity on the
SCORAD excoriation item. Similarly, the association of peak itch
severity with pain/discomfort was evaluated at baseline from the
data pooled from SOLO 1&2 + CHRONOS trials; itch severity
was measured using a numerical rating scale with severity strata of
0 to 3 for no/mild, 4 to 6 for moderate, and 7 to 10 for severe itch.31
All analyses were conducted using SAS, version 9.2 or above
(SAS Institute, Cary, NC).
RESULTS
Population Characteristics
In each of the trials, baseline demographic and disease characteris-
tics were balanced across treatment groups (Table 1). The propor-
tions of patients who reported moderate-to-extreme pain/discomfort
at baseline on the EQ-5D-3L were generally similar across treatment
groups and across the trials (Fig. 1) and ranged from 72.9% to 83.1%;
“no pain/discomfort” was reported at baseline by less than a quarter
of the patients, regardless of the trial or treatment arm (17.0%–24.1%).
Impact of Dupilumab on Pain/Discomfort
The proportions of patients treated with dupilumab, with or with-
out TCS, who reported “no pain/discomfort” on EQ-5D-3L after
16 weeks of treatment ranged from 51.4% to 70.1% for the 300 mg
q2w dose, from 48.3% to 62.7% for the 300 mg qw dose, and from
19.7% to 37.0% for placebo with or without TCS (Fig. 2); risk differ-
ences ranged from 22.3% (95% CI = 11.5%–33.1%) to 42.2% (95%
CI = 26.6%–57.8%, all P ≤ 0.0001). Both dupilumab treatment
groups showed significant difference from placebo at week 1 in
SOLO 1&2 and CAFÉ (Figs. 2B, C) that was sustained through
the end of the study period. In CHRONOS, significant difference
from placebo + TCS was observed at week 2 for dupilumab
300 mg qw + TCS and at week 4 for dupilumab 300 mg q2w + TCS
(Fig. 2D), with these effects maintained over the 52 weeks; risk dif-
ferences at week 52 were 33.5% (95% CI = 17.7%–49.2%) and 42.2%
(95% CI = 26.6%–57.8%) for the dupilumab q2w and qw treatment
groups, respectively (both P ≤ 0.0001).
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TABLE 1. Baseline Characteristics Among the Treatment Groups in the Phase 2b Dose Ranging, SOLO 1&2 (Pooled), CHRONOS, and CAFÉ
Studies
Variable

















































































































































































































































































































































































































































































DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; HADS-A, Hospital Anxiety and Depression Scale–Anxiety Subscale; HADS-D, Hospital Anxiety and Depression Scale–Depression Subscale; IGA,































Correlation of Pain/Discomfort With Other AD
Assessments
Correlations at baseline were weak between pain/discomfort and
AD signs (EASI and SCORAD individual signs) and were of mod-
erate strength for the total SCORAD score and other AD symptoms,
including peak pruritus NRS and POEM (Table 2, Fig. 3). Baseline
correlations were also moderate between pain/discomfort and
HRQoL, as well as symptoms of anxiety and depression (Table 2).
By contrast, among patients who had moderate-to-severe pain/
discomfort at baseline, correlations of change in pain/discomfort
at week 16 with changes in the total SCORAD score and the individ-
ual SCORAD signs were strong (Table 2). However, for other out-
comes at week 16, the correlations between change in pain/discomfort
ranged from weak (EASI, HADS-A) to moderate (POEM, DLQI,
and HADS-D) strength (Table 2).
Pain/discomfort was reported by at least half of the patients, re-
gardless of SCORAD excoriation severity, including 50.0% to
83.4% of the few patients who had no excoriations (Fig. 4). Except
for a slightly higher proportion of patients with severe pain among
the patients with severe SCORAD excoriations, the pattern of pain/
discomfort in all 4 studies was generally similar across the excoriation
severity categories, with moderate pain/discomfort reported by 50.0%
to 74.5% of the patients (Fig. 4).
DISCUSSION
This study provides support for the presence of pain/discomfort in a
substantial proportion of patients with AD. The lack of strong base-
line correlations between pain/discomfort and other measures of
AD signs and symptoms suggests that pain may be a distinct symp-
tom in patients with AD and should be assessed independently,
both as a measure of disease burden and as an outcome of treatment
benefit. Such assessment is consistent with the recommendation of
the Harmonizing Outcome Measures for Eczema group to explore
the importance of pain in the treatment of AD.32 The results of this
study further suggest that treatment with dupilumab, with or without
topical steroids, alleviates pain/discomfort in a significantly higher pro-
portion of patients relative to placebo or TCS. Effects of dupilumab
on pain/discomfort were consistently observed early after treatment
initiation and were maintained throughout treatment duration,
with most patients achieving no pain/discomfort at week 16.
In 2 recent cross-sectional studies of patients with AD from clinical
practice settings in North America and Europe, higher pain severity
Figure 1. Pain/discomfort at baseline as reported by the patients on the EQ-5D pain/discomfort dimension.
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was reported by the patients with more severe AD.33,34 However,
large SDs in pain scores in these studies suggest wide variability in
presence and perceptions of pain across patients. The patient-reported
burden of skin symptoms, HRQoL, sleep, andmental health increases
with greater pain severity, with itch and pain showing additive effects.10
Pain/discomfort in AD is likely multifactorial, resulting from a
variety of sources. These sources may include disease pathology,
causing pain that is secondary to intense cutaneous inflammation
or as an effect of broken (cracked, fissured, excoriated) skin, infec-
tions, and scratching in response to itch. However, it should be
noted that a substantial proportion of patients reported pain/
discomfort regardless of the presence and severity of excoriations
indicative of scratching. Although a previous study found that pa-
tients commonly reported pain that originated from scratching,15
the presence of moderate pain/discomfort in similar proportions
of patients across excoriation severity categories in all studies sug-
gests that such pain/discomfort is, at least in part, independent of
scratching. Pain/discomfort may also potentially result from the
stinging/burning after application of topical products, although
poor tolerability of topicals has been reported as a cause of pain in
only a few (10%) of the patients with AD pain.15
Across the dupilumab phase 3 studies, correlations of pain/
discomfort with AD individual signs and symptoms were weak at
baseline, including for excoriations. These weak correlations support
the hypothesis that pain/discomfort in patients with AD is not neces-
sarily a secondary manifestation of scratching, lesions, or otherwise
damaged skin. Correlations with DLQI and HADS were moderate
at baseline.
At the end of treatment, improvement in pain/discomfort was
strongly correlated with the total SCORAD and each of the SCORAD
individual signs. Although the effects of pain on HRQoL are well
recognized,35 the stronger correlations at end of treatment relative
to baseline between pain/discomfort and the total SCORAD and
SCORAD individual signs may be suggestive of the overall effect
of dupilumab treatment on the underlying disease rather than a di-
rect relationship between these outcomes. Thus, evidence from this
study and others suggests that treatment efficacy related to pain
should be assessed independent of skin-related signs and symptoms,
Figure 2. Proportions of patients who reported “no pain/discomfort” on the EQ-5D pain/discomfort dimension over the duration of the studies. Num-
bers are shown only for baseline, first significant time point versus placebo, week 16, and week 52 (CHRONOS). Values after first rescue treatment
were set to missing (censored), and patients with missing responses at week 16were considered nonresponders. *P≤ 0.0001 and †P< 0.05 versus
placebo.
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including itch; the nociceptive complaints in AD may be related to
both peripheral and central neural sensitization that is common in
inflammatory skin diseases.36,37
The mechanism by which dupilumab reduces pain in AD is not
clear, but its demonstrated efficacy in AD stems from binding to
IL-4Rα, thus inhibiting both IL-4 and IL-13 signaling pathways.38
Dupilumab has been shown to significantly alleviate inflammatory
skin lesions and help restore skin integrity39,40; reducing inflamma-
tion can be expected to result in lower levels of inflammatory medi-
ators of pain, and skin integrity may protect sensory nerve endings
against external nociceptive stimuli.
Mechanisms involved in the transduction and generation of itch
and pain have been extensively reviewed,41–43 and both IL-4 and
IL-13 signaling pathways may be involved in nociceptive signal pro-
cessing.44 In addition, IL-4Rα seems to mediate chronic itch by sen-
sitizing sensory neurons to pruritogens, with the type 2 inflammatory
cytokines IL-4 and IL-13 demonstrating an ability to activate
itch-sensory pathways in human sensory neurons.45,46 Because
these neurons are nociceptors, the implication is that they can
conduct both itch and pain signals. This overlap and crosstalk be-
tween itch and pain pathways may account for the observation
that in patients with AD, stimuli that are normally painful have
been reported to evoke itching.47,48 This also suggests that by
blocking IL-4 and IL-13 signaling in sensory neurons, dupilumab
may potentially have a dual effect on itch and pain, which is sup-
ported by the recent report that molecular effects induced by
dupilumab include downregulation of IL-31.40 Interleukin-31
and its receptor have been shown to be associated with itch and
pain signaling, with effects that suggest pain and itch pathways
share nerve fibers.49,50 Further analyses are warranted to explore
the extent to which the effects of dupilumab on pain are direct or
mediated through reduction of itch.
TABLE 2. Correlation Between EQ-5D-3L Pain/Discomfort Dimension With AD Outcomes Using Pooled Data
From the SOLO 1&2 + CHRONOS Studies
Correlation n Spearman r (95% CI) P
Baseline scores
SCORAD*
Total score 2119 0.317 (0.278–0.354) <0.0001
Erythema 2119 0.167 (0.125–0.208) <0.0001
Edema/papulation 2119 0.160 (0.118–0.201) <0.0001
Oozing/crusting 2119 0.125 (0.083–0.166) <0.0001
Excoriation 2119 0.150 (0.108–0.191) <0.0001
Lichenification 2119 0.068 (0.025–0.110) 0.0018
Dryness 2119 0.052 (0.009–0.094) 0.0176
EASI 2117 0.215 (0.174–0.256) <0.0001
Peak pruritus NRS 2112 0.391 (0.354–0.426) <0.0001
POEM 2116 0.436 (0.401–0.470) <0.0001
DLQI 2117 0.477 (0.443–0.509) <0.0001
HADS-A 2045 0.328 (0.288–0.366) <0.0001
HADS-D 2045 0.370 (0.332–0.407) <0.0001
Change from baseline at week 16†
SCORAD*
Total score 1707 0.748 (0.726–0.768) <0.0001
Erythema 1707 0.628 (0.598–0.655) <0.0001
Edema/papulation 1707 0.644 (0.615–0.671) <0.0001
Oozing/crusting 1707 0.652 (0.624–0.678) <0.0001
Excoriation 1707 0.668 (0.641–0.693) <0.0001
Lichenification 1707 0.628 (0.599, 0.656) <0.0001
Dryness 1707 0.582 (0.550–0.613) <0.0001
EASI 1601 0.296 (0.251–0.340) <0.0001
Peak pruritus NRS 1582 0.422 (0.381–0.462) <0.0001
POEM 1598 0.465 (0.426–0.503) <0.0001
DLQI 1600 0.462 (0.423–0.500) <0.0001
HADS-A 1548 0.267 (0.220–0.312) <0.0001
HADS-D 1546 0.338 (0.293–0.382) <0.0001
*Missing scores were set to worst case for both pain and SCORAD.
†Patients with moderate-to-severe EQ-5D-3L pain/discomfort at baseline.
CI, confidence interval; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; HADS-A, Hospital Anxiety and Depression Scale–Anxiety Subscale; HADS-
D, Hospital Anxiety and Depression Scale–Depression Subscale; NRS, numerical rating scale; POEM, Patient-Oriented Eczema Measure; SCORAD, Scoring Atopic Dermatitis.
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Strengths and Limitations
A key strength of this analysis is the ability to examine the preva-
lence and burden of pain and to evaluate the efficacy of dupilumab
on pain, in a large international sample of 2632 patients with AD
across multiple clinical trials conducted in 28 countries. In addition,
concurrent assessment of several patient and clinician-reported
measures of AD signs, symptoms, and HRQoL allowed exploration
of the relationship between pain and these other domains. A limita-
tion of this study is the use of a broad assessment of pain/discomfort
rather than a more specific assessment of skin pain. However, the re-
sults regarding the presence and impact of pain are consistent with re-
cent studies that specifically assessed skin pain in patients with AD.10,11
Figure 3. Association of peak itch severity with pain/discomfort using the baseline data pooled from the SOLO 1&2 + CHRONOS trials.
Figure 4. Association of the SCORAD excoriation severity with pain/discomfort using the baseline data of pooled treatment groups.
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CONCLUSIONS
Observations across studies, including this report, suggest that pain
is common in AD. Although painmay comprise part of a mechanis-
tically overlapping spectrum of discomforting sensations that in-
cludes itch, it likely represents a distinct symptom of AD and is
reported by a substantial proportion of patients with AD, regardless
of the presence and severity of excoriations. Consistent results from
multiple clinical trials demonstrated that dupilumab with and with-
out TCS reduced pain/discomfort in adults with moderate-to-severe
AD and that this reduction is likely to be, at least in part, indepen-
dent of its effects on itch. Although further research is needed to en-
hance our understanding of pain in ADwith regard to its prevalence
and pathways of initiation and propagation, the overall implications
of the accumulating data reflect the need for regular assessment of
pain and its effects on AD, both in clinical trials and with regard
to patient management strategies in clinical practice.
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